Frontlight ResearchEarly access
CompletedEarly phase 1
The Effects of Chicken Extract and a Peptide Supplement for the Prevention of Cognitive Decline in Non-demented Elderly Adults
Key facts
- Who runs it
- Brand's Suntory Asia
- Where
- Taiwan3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 276 people enrolled
- Started
- 11 Dec 2020
- Ended
- 8 Jan 2025
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Chicken extract supplement
- Peptide Supplement
- Placebo
- Record updated
- 16 September 2025
Who can take part
- Age
- 55 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Male or female at 55 - 75 years of age
- Baseline cognition:
- Normal cognition with feelings of cognitive decline (subjective cognitive decline) OR
- Mild cognitive impairment (MCI+) with memory impairment
- Agree to participate in the study and provide written informed consent
Who cannot take part
- Regular use of any medication in the past 6 months that may affect cognitive functioning
- Subjects with excessive blood donation or blood drawn prior to baseline
- Significant cerebrovascular disease
- History of allergy to chicken meat
- Diagnosis of Alzheimer's disease (AD) with dementia or any other dementia
- Clinical dementia rating (CDR) score of > 0.5 at screening
- Evidence of other neurological, psychiatric or physical illness that can produce cognitive deterioration per investigator's judgment
- Current diagnosis or history of alcoholism or substance addiction
- Persons with a history of cardiovascular disease or any other cardiovascular or cerebrovascular diseases which investigators deem unsuitable to participate in the clinical study
- Inadequate visual and auditory acuity to allow neuropsychological testing
- Inability or unwillingness to undergo PET scan
- Regular use of cognitive enhancing supplements in the past 6 months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This trial investigates the effect of a chicken extract supplement and a peptide supplement on cognitive function and potential mechanisms of action of cognitive decline during ageing, among non-demented elderly adults using a three-arm, randomized, placebo-controlled clinical trial design.
The 3 groups in the trial
- Chicken extract supplementTreatment being tested
- Peptides supplementTreatment being tested
Treatment: Peptide Supplement
- PlaceboPlacebo, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Trial of A Chicken Extract and Peptide Supplement for the Prevention of Cognitive Decline and Mechanisms of Action in Non-demented Elderly Adults: A Multicenter, Two-year, Three-arm, Randomized, Double-blind, Placebo-controlled Study
- Record updated
- 16 September 2025